Mayinglong Pharmaceutical Group Co., LTD. (600993.SS)
CNY 26.3
(0.88%)
CNY 26.3
(0.88%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 3.13 Billion | 3.53 Billion | 3.38 Billion | 2.79 Billion | 2.7 Billion | 2.19 Billion |
| Cost of Revenue | 1.82 Billion | 2.03 Billion | 2.01 Billion | 1.66 Billion | 1.59 Billion | 1.2 Billion |
| Gross Profit | 1.3 Billion | 1.49 Billion | 1.36 Billion | 1.12 Billion | 1.1 Billion | 991.03 Million |
| Operating Expenses | 778.04 Million | 971.43 Million | 893.26 Million | 744.83 Million | 719.33 Million | 672.87 Million |
| Selling, General and Administrative Expenses | 750.54 Million | 816.47 Million | 753.74 Million | 637.06 Million | 613.51 Million | 570.04 Million |
| Research and Development Expenses | 69.01 Million | 77.89 Million | 66.73 Million | 55.66 Million | 55.29 Million | 40.88 Million |
| Other Expenses | -7.01 Million | 77.07 Million | 72.78 Million | 52.1 Million | 50.52 Million | -1.49 Million |
| Cost and Expenses | 2.6 Billion | 3 Billion | 2.91 Billion | 2.4 Billion | 2.31 Billion | 1.87 Billion |
| Operating Income | 536.62 Million | 555.53 Million | 550.3 Million | 500.47 Million | 424.59 Million | 193.23 Million |
| Interest Expense | 16.65 Million | 11.68 Million | 10.2 Million | 6.98 Million | 5.14 Million | 4.11 Million |
| Income Tax Expense | 72.86 Million | 78.82 Million | 74.1 Million | 67.04 Million | 69.01 Million | 27.17 Million |
| Earnings before Tax | 524.7 Million | 559.13 Million | 548.15 Million | 497.69 Million | 422.41 Million | 191.73 Million |
| Net Income | 443.25 Million | 478.57 Million | 464.59 Million | 419.05 Million | 359.96 Million | 176.2 Million |
| Earnings Per Share Basic | 1.03 | 1.11 | 1.08 | 0.97 | 0.84 | 0.41 |
| Earnings Per Share Diluted | 1.03 | 1.11 | 1.08 | 0.97 | 0.84 | 0.41 |
| Weighted Average Shares Outstanding | 430.34 Million | 431.05 Million | 431.05 Million | 431.05 Million | 431.05 Million | 429.77 Million |
| Weighted Average Shares Outstanding (Diluted) | 430.34 Million | 431.05 Million | 431.05 Million | 431.05 Million | 431.05 Million | 429.77 Million |
| Gross Margin | 0.42 | 0.42 | 0.40 | 0.40 | 0.41 | 0.45 |
| EBIT Margin | 0.20 | 0.20 | 0.19 | 0.16 | 0.17 | 0.18 |
| Profit Margin | 0.14 | 0.14 | 0.14 | 0.15 | 0.13 | 0.08 |
| EBITDA | 633.25 Million | 654.65 Million | 619.5 Million | 552.17 Million | 478.18 Million | 232.2 Million |
| Earnings Before Tax Margin | 0.17 | 0.16 | 0.16 | 0.18 | 0.16 | 0.09 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 864.1 Million | 968.7 Million | 945.44 Million | 3.11 Billion | 690.5 Million | 805.89 Million |
| Cost of Revenue | 462.47 Million | 522.14 Million | 484.04 Million | 1.82 Billion | 437.03 Million | 462.84 Million |
| Gross Profit | 401.62 Million | 446.56 Million | 461.39 Million | 1.29 Billion | 253.47 Million | 343.04 Million |
| Operating Expenses | 230.76 Million | 315.62 Million | 242.05 Million | 898.48 Million | 258.79 Million | 188.13 Million |
| Selling, General and Administrative Expenses | 399.82 Million | 293.58 Million | 224.8 Million | - | 166.67 Million | 214.98 Million |
| Research and Development Expenses | 16.93 Million | 15.58 Million | 16.78 Million | - | 20.62 Million | 13.84 Million |
| Other Expenses | -185.99 Million | -6.44 Million | -460.85 Thousand | 62.83 Million | -6.08 Million | -2.83 Million |
| Cost and Expenses | 693.24 Million | 837.77 Million | 726.1 Million | 2.73 Billion | 695.83 Million | 650.98 Million |
| Operating Income | 183.01 Million | 130.93 Million | 219.34 Million | 536.62 Million | 26.2 Million | 162.83 Million |
| Interest Expense | - | 3.02 Million | 1.93 Million | 16.85 Million | 3.11 Million | 4.92 Million |
| Income Tax Expense | 32.51 Million | 27.12 Million | 37.12 Million | 72.86 Million | -2.74 Million | 23.62 Million |
| Earnings before Tax | 181.02 Million | 146.19 Million | 239.01 Million | 522.98 Million | 18.71 Million | 160.34 Million |
| Net Income | 145.59 Million | 114.24 Million | 197.66 Million | 443.25 Million | 24.86 Million | 137.01 Million |
| Earnings Per Share Basic | 0.34 | 0.27 | 0.46 | - | 0.06 | 0.32 |
| Earnings Per Share Diluted | 0.34 | 0.27 | 0.46 | - | 0.06 | 0.32 |
| Weighted Average Shares Outstanding | 431.05 Million | 431.05 Million | 431.05 Million | 431.05 Million | 431.05 Million | 431.05 Million |
| Weighted Average Shares Outstanding (Diluted) | 431.05 Million | 431.05 Million | 431.05 Million | 431.05 Million | 431.05 Million | 431.05 Million |
| Gross Margin | 0.46 | 0.46 | 0.49 | 0.41 | 0.37 | 0.43 |
| EBIT Margin | 0.21 | 0.16 | 0.26 | - | 0.03 | 0.21 |
| Profit Margin | 0.17 | 0.12 | 0.21 | 0.14 | 0.04 | 0.17 |
| EBITDA | 180.09 Million | 152.84 Million | 246.49 Million | - | 22.06 Million | 167.73 Million |
| Earnings Before Tax Margin | 0.21 | 0.14 | 0.23 | 0.17 | 0.04 | 0.20 |
001230
002023
603931
ESLA
CNNC
CBOX